1610791-09-7

Basic information

• Product Name: C₃₀H₃₁ClO₇S
• Synonyms: C₃₀H₃₁ClO₇S
• CAS NO: 1610791-09-7
• Molecular Weight: 571.091
• Mol File: 1610791-09-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₃₀H₃₁ClO₇S(CAS DataBase Reference)
• NIST Chemistry Reference: C₃₀H₃₁ClO₇S(1610791-09-7)
• EPA Substance Registry System: C₃₀H₃₁ClO₇S(1610791-09-7)

Safety Data

• Hazardous Substances Data: 1610791-09-7(Hazardous Substances Data)

Upstream product

• 596087-18-2 4-methylphenyl 2,3-di-O-benzyl-1-thio-β-D-glucopyranoside 
• 100-39-0 benzyl bromide 
• 1352561-81-9 C₂₈H₃₀O₆S 
• 541-88-8 Chloroacetic anhydride 
• 850416-39-6 p-methylphenyl 2,3-di-O-benzyl-4,6-O-(R)-benzylidene-1-thio-β-D-glucopyranoside 
• 219518-19-1 4-methylphenyl 4,6-O-benzylidene-1-thio-β-D-glucopyranoside 

Downstream Products

• 87907-01-5 methyl (2,3-di-O-benzyl-4-O-chloroacetyl-α-D-glucopyranosyl bromide)uronate 
• 87907-02-6 O-(methyl 2,3-di-O-benzyl-4-O-(chloroacetyl)-β-D-glucopyranosyluronate)-(1->4)-3-O-acetyl-1,6-anhydro-2-azido-2-deoxy-β-D-glucopyranose 
• 99541-26-1 O-(methyl 2,3-di-O-benzyl-β-D-glucopyranosyluronate)-(1->4)-3-O-acetyl-1,6-anhydro-2-azido-2-deoxy-β-D-glucopyranose 
• 99541-27-2 O-(6-O-acetyl-2-azido-3,4-di-O-benzyl-2-deoxy-α-D-glucopyranosyl)-(1->4)-O-(methyl 2,3-di-O-benzyl-β-D-glucopyranosyluronate)-(1->4)-3-O-acetyl-1,6-anhydro-2-azido-2-deoxy-β-D-glucopyranose 
• 135362-96-8 O-(6-O-acetyl-2-azide-3,4-di-O-benzyl-2-deoxy-2-α-D-glucopyranosyl)-(1→4)-O-(methyl 2,3-di-O-benzyl-β-D-glucopyranosyluronate)-(1→4)-3,6-di-O-acetyl-2-azido-2-deoxy-β-D-glucopyranosyl trichloroacetimidate 
• 135362-95-7 O-(6-O-acetyl-2-azide-3,4-di-O-benzyl-2-deoxy-2-α-D-glucopyranosyl)-(1→4)-O-(methyl 2,3-di-O-benzyl-β-D-glucopyranosyluronate)-(1→4)-3,6-di-O-acetyl-2-azido-2-deoxy-α-D-glucopyranosyl trichloroacetimidate 

Relevant articles and documents

Total synthesis of anticoagulant pentasaccharide fondaparinux

The anticoagulant pentasaccharide fondaparinux was synthesized using an improved and optimized synthetic strategy including a convergent [3+2] coupling approach, orthogonal protecting groups and various glycosyl donors. The new methods of glycosylation were also used for controlling the stereochemical configuration and improving the yield of the glycosylation. In addition, HPLC and NMR methods to monitor the process of total synthesis of fondaparinux were employed. This work provides a comprehensive elaboration for the synthesis and analysis of fondaparinux based on related literature, as well as abundant information for the synthesis of heparin-like oligosaccharides. A matter of protection! The anticoagulant pentasaccharide fondaparinux was synthesized using an improved and optimized synthetic strategy. The process of total synthesis was monitored by HPLC and NMR. This work will contribute to continued improvement of the multistep production of fondaparinux and provide abundant information for the synthesis of heparin-like oligosaccharides.